BridgeBio Oncology Therapeutics, Inc. Financial Flexibility Index
BridgeBio Oncology Therapeutics, Inc. financial flexibility index. BridgeBio Oncology Therapeutics, Inc. (BBOT) has a Financial Flexibility Index of -0.79x as of March 2026. Free cash flow of $-35.89 Million (operating CF $-35.92 Million minus capex $24.00K) represents -1% of total liabilities ($45.37 Million).
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of BridgeBio Oncology Therapeutics, Inc. (2023–2025)
Financial flexibility index of BridgeBio Oncology Therapeutics, Inc. from 2023 to 2025. Historical Financial Flexibility Index trend for BridgeBio Oncology Therapeutics, Inc. across 3 annual periods. Check how high is BridgeBio Oncology Therapeutics, Inc.'s earnings quality to evaluate the quality of earnings relative to operating cash generation.
BridgeBio Oncology Therapeutics, Inc. Financial Flexibility Index by Year (2023–2025)
BridgeBio Oncology Therapeutics, Inc. financial flexibility index by year from 2023 to 2025. Year-by-year free cash flow to debt coverage for BridgeBio Oncology Therapeutics, Inc.. For the full cash flow conversion analysis, see cash efficiency ratio of BridgeBio Oncology Therapeutics, Inc..
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -3.04x | $-113.29 Million | $-113.89 Million | $37.28 Million | ▼ -2326.1% |
| 2024 | -0.13x | $-714.82K | $-763.82K | $5.71 Million | ▲ +99.9% |
| 2023 | -130.31x | $-51.66 Million | $-52.08 Million | $396.46K | — |